RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights

Author's Avatar
May 10, 2018
Article's Main Image

- Reduced cash burn per quarter by 20% from $2.5 million to $2 million

- Expect to expand external collaborations in the coming months in IO and ACT

- Publication in Molecular Therapy on self-delivering RNAi targeting PD-1 in ACT for the treatment of malignant melanoma

PR Newswire